Physiomics Appoints a New Chief Executive Officer

Further to the announcement of 31 March 2016, the Company confirms that Dr James Simon Millen, aged 47 is to be appointed Chief Executive Officer of the Company with effect from today (18th April 2016). Dr James Millen, known also as Jim, has experience of drug development and of licensing deals in global pharma companies. The Company also confirms that Dr Mark Chadwick will step down as Chief Executive Officer today, but as previously announced will remain on the Board of Physiomics as a NED for the foreseeable future.

Read more